Non-muscle-invasive Bladder Cancer

This course compiles the most recent clinical guidelines edited by the EAU in relation to Non-muscle Invasive Bladder Cancer. The Non-muscle Invasive Bladder Cancer course is divided into 3 learning units. Each Learning Unit consists of multiple choice questions that you can answer by navigating to the corresponding chapter of the Non-muscle Invasive Bladder Cancer guideline. The questions are offered for self-assessment of your knowledge of the EAU Guidelines on Non-muscle Invasive Bladder Cancer.

Generally speaking, while NMIBCs have a more favourable prognosis compared to their MI counterpart, they are not the same and seem to behave differently (i.e. some are relatively indolent, others have aggressive features). In this episode, Prof. Paolo Gontero (IT) explains why this is the case.

Patients with non-muscle-invasive bladder cancer (NMIBC) recurrence during or after chemotherapy can benefit from BCG instillations. BCG therapy is effective regardless of prior chemotherapy. For those who fail BCG treatment, additional strategies, including further BCG therapy, may improve outcomes.

Bladder cancer (BC) is the 7th most commonly diagnosed cancer in males. Bladder cancer incidence and mortality rates vary across countries. Approximately 75% of patients with BC are non-muscle-invasive bladder carcinomas (NMIBC).

Review the EAU Guidelines on the risk stratification and disease management of NMIBC with this Cheat Sheet.

Follow-up after TURB is risk-adapted.
🔹 Low-risk: May stop cystoscopy after 5 years.
🔹 Intermediate-risk: Cystoscopy at 3 months, then every 6–12 months.
🔹 High-risk: Lifelong cystoscopy, urine cytology, upper tract monitoring.
🔹 No marker replaces cystoscopy.